Skip to content

Dexmedetomidine and Propofol for Pediatric MRI Sedation

An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03513757
Enrollment
40
Registered
2018-05-02
Start date
2018-03-04
Completion date
2018-10-21
Last updated
2020-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity

Brief summary

The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. The investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, the investigators will administer whatever is necessary. At the end of the study, the investigators will have an observer record the time it takes for participants to spontaneously open eyes , to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that the investigators find out from participants about changes in behavior, or if eating or sleeping habits were unusual following completion of the study. For that reason, the investigators will call participants in a day or so following the MRI scan. The investigators expect to recruit 40 children between the ages of 12 and 72 months for the study and hope to have the study completed in December 2018.

Detailed description

The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). Recent studies and the FDA have raised concerns that anesthesia for longer than three hours may have effects on behavior and learning. Although investigators do not know if these effects are caused by drugs or the medical condition a child is being treated for, in December 2016, the FDA published the information below regarding anesthesia for children: General anesthetic and sedation drugs are used to put people into a deep sleep so they do not feel pain during surgery or procedures. These drugs are usually injected into a vein or breathed in through a mask. General anesthetic and sedation drugs are widely used to ensure the health, safety, and comfort of children and adults undergoing surgery or other procedures. Recent studies in children suggest that a single, relatively short exposure to general anesthetic and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning. More research is still needed to fully understand how anesthetics might affect brain development, especially longer or repeated exposures and in more vulnerable children. Anesthetic and sedation drugs are necessary for infants, children, and pregnant women who require surgery or other painful and stressful procedures. https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm Research in neonatal and infant animals has demonstrated that sedative and anesthetic agents, like propofol, produce adverse effects on brain development, including loss of brain cells resulting in long-term, possibly permanent changes in learning and behavior. These adverse effects appear to occur mostly after prolonged periods of sedation or anesthesia (generally greater than 3 hours) and when brain development is occurring at a rapid rate (which roughly occurs in children under 3 years of age). It is not known if similar adverse effects occur in humans. Study participants should be advised that the drugs used to accomplish the procedure may have the potential to increase the loss of nerve cells in the developing brain of young child and that the clinical significance of any such changes is not known. There are some animal studies that suggests dexmedetomidine may be better for a growing infant's brain. However, the effects of dexmedetomidine alone or in combination with propofol on the developing brain have not been thoroughly tested to date. The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. Investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, investigators will administer whatever is necessary. At the end of the study, an observer will record the time it takes for spontaneous eye opening, to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that investigators learn in the following day or two how the participant behaved at home; whether eating, behavior and sleeping were unusual. For that reason, the investigator will call the participant a day or so following the MRI scan. The investigators expect to recruit 70 children between the ages of 12 and 72 months for the study and hope to have the study completed in 2018.

Interventions

DRUGpropofol

propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists

DRUGDexmedetomidine

single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg

DRUGGlycopyrrolate

4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group

1 mg/kg intravenous administration prior to propofol administration

DRUGNitrous Oxide

Inhalation of nitrous oxide may be used for IV placement

DRUGSevoflurane

Inhalation of sevoflurane may be used for IV placement

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

The patients and their parents/guardians as well as the blinded observer or investigator who participates in outcomes assessment will be blinded to the drug or drugs administered.

Intervention model description

observer blinded comparison of propofol with low-dose propofol and dexmedetomidine for pediatric MRI sedation

Eligibility

Sex/Gender
ALL
Age
12 Months to 60 Months
Healthy volunteers
No

Inclusion criteria

* All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.

Exclusion criteria

* Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders. * All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusionthrough study completion, an average of 2 hoursTime (minutes) from anesthesia start to readiness for discharge from the department to home or clinic.

Secondary

MeasureTime frameDescription
Eye Openingup to 90 minutesminutes from completion of scan to spontaneous eye opening
Oral/Enteral Intakeup to 2 hoursminutes from completion of scan to oral/enteral intake
Total Propofol Administeredup to 90 minutestotal propofol administered (mg/kg)
Dexmedetomidine Doseup to 90 minutesdexmedetomidine dose (mcg/kg)
Glycopyrrolate Dose5 minutesglycopyrrolate dose (mcg/kg)
Sevofluranesevoflurane induction time up to 10 minutessevoflurane induction time of 5 minutes
Nitrous Oxideup to 10 minutesdocumentation of use
Discharge Readyup to 2 hoursminutes from completion of scan to discharge ready
Sleep Patternup to 48 hoursparental observation of deviation from child's normal habit obtained through follow-up phone call
Irritabilityup to 48 hoursbehavior deemed inappropriate and a deviation from child's normal though parental observation obtained through follow-up phone call
Deliriumup to 24 hours.Pediatric Anesthesia Emergence Delirium (PAED) score greater than 12 as defined by Sikich and Lerman. 0 = no delirium, 20 = worst possible delirium; 5 categories scored from 0-4 additive for a maximum score of 20. Categories 1-3 are scored the same and categories ar scored inversely as described. 1. Child makes contact with caregiver, 2. child's actions are purposeful, 3. child is aware of his surroundings. For each of these category, score 0 for extremely, 1 for very much, 2 for quite a bit, 3 for just a little, 4 for not at all. The other 2 categories 4. Child is restless and 5 Child is inconsolable are scored as 0 for not at all, 1 for just a little, 2 for quite a bit, 3 for very much, 4 for extremely
Lidocaine Doseup to 90 minuteslidocaine dose (mg/kg)

Countries

United States

Participant flow

Participants by arm

ArmCount
Propofol
Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mic/kg/min. Dose will be increased by 50 mic/kg/min up to 300 mic/kg/min for movement and decreased to 150 mic/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions. propofol: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 200 mic/kg/minute propofol infusion if movement persists
22
Propofol Dexmedetomidine
Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mic/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mic/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mic/kg/min. Study to be terminated if movement persists despite above interventions. propofol: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 200 mic/kg/minute propofol infusion if movement persists Dexmedetomidine: single dose dexmedetomidine administered at start of sedation. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mic/kg
18
Total40

Baseline characteristics

CharacteristicPropofol DexmedetomidineTotalPropofol
Age, Continuous26 months34 months39 months
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
18 Participants40 Participants22 Participants
Sex: Female, Male
Female
7 Participants16 Participants9 Participants
Sex: Female, Male
Male
11 Participants24 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 18
other
Total, other adverse events
13 / 2210 / 18
serious
Total, serious adverse events
0 / 220 / 18

Outcome results

Primary

Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion

Time (minutes) from anesthesia start to readiness for discharge from the department to home or clinic.

Time frame: through study completion, an average of 2 hours

ArmMeasureValue (MEDIAN)
PropofolEfficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion98 minutes
Propofol DexmedetomidineEfficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion77 minutes
Secondary

Delirium

Pediatric Anesthesia Emergence Delirium (PAED) score greater than 12 as defined by Sikich and Lerman. 0 = no delirium, 20 = worst possible delirium; 5 categories scored from 0-4 additive for a maximum score of 20. Categories 1-3 are scored the same and categories ar scored inversely as described. 1. Child makes contact with caregiver, 2. child's actions are purposeful, 3. child is aware of his surroundings. For each of these category, score 0 for extremely, 1 for very much, 2 for quite a bit, 3 for just a little, 4 for not at all. The other 2 categories 4. Child is restless and 5 Child is inconsolable are scored as 0 for not at all, 1 for just a little, 2 for quite a bit, 3 for very much, 4 for extremely

Time frame: up to 24 hours.

ArmMeasureValue (NUMBER)
PropofolDelirium0 participants
Propofol DexmedetomidineDelirium0 participants
Secondary

Dexmedetomidine Dose

dexmedetomidine dose (mcg/kg)

Time frame: up to 90 minutes

ArmMeasureValue (MEDIAN)
PropofolDexmedetomidine Dose0 mcg/kg
Propofol DexmedetomidineDexmedetomidine Dose0.70 mcg/kg
Secondary

Discharge Ready

minutes from completion of scan to discharge ready

Time frame: up to 2 hours

ArmMeasureValue (MEDIAN)
PropofolDischarge Ready40 minutes
Propofol DexmedetomidineDischarge Ready17 minutes
Secondary

Eye Opening

minutes from completion of scan to spontaneous eye opening

Time frame: up to 90 minutes

ArmMeasureValue (MEDIAN)
PropofolEye Opening28 minutes
Propofol DexmedetomidineEye Opening3 minutes
Secondary

Glycopyrrolate Dose

glycopyrrolate dose (mcg/kg)

Time frame: 5 minutes

ArmMeasureValue (MEDIAN)
PropofolGlycopyrrolate Dose0 mcg/kg
Propofol DexmedetomidineGlycopyrrolate Dose4.2 mcg/kg
Secondary

Irritability

behavior deemed inappropriate and a deviation from child's normal though parental observation obtained through follow-up phone call

Time frame: up to 48 hours

ArmMeasureValue (NUMBER)
PropofolIrritability3 participants
Propofol DexmedetomidineIrritability0 participants
Secondary

Lidocaine Dose

lidocaine dose (mg/kg)

Time frame: up to 90 minutes

ArmMeasureValue (MEDIAN)
PropofolLidocaine Dose1.00 mg/kg
Propofol DexmedetomidineLidocaine Dose1.00 mg/kg
Secondary

Nitrous Oxide

documentation of use

Time frame: up to 10 minutes

ArmMeasureValue (NUMBER)
PropofolNitrous Oxide18 participants
Propofol DexmedetomidineNitrous Oxide17 participants
Secondary

Oral/Enteral Intake

minutes from completion of scan to oral/enteral intake

Time frame: up to 2 hours

ArmMeasureValue (MEDIAN)
PropofolOral/Enteral Intake33 minutes
Propofol DexmedetomidineOral/Enteral Intake14 minutes
Secondary

Sevoflurane

sevoflurane induction time of 5 minutes

Time frame: sevoflurane induction time up to 10 minutes

ArmMeasureValue (NUMBER)
PropofolSevoflurane18 participants
Propofol DexmedetomidineSevoflurane17 participants
Secondary

Sleep Pattern

parental observation of deviation from child's normal habit obtained through follow-up phone call

Time frame: up to 48 hours

ArmMeasureValue (NUMBER)
PropofolSleep Pattern3 participants
Propofol DexmedetomidineSleep Pattern2 participants
Secondary

Total Propofol Administered

total propofol administered (mg/kg)

Time frame: up to 90 minutes

ArmMeasureValue (MEDIAN)
PropofolTotal Propofol Administered10.6 mg/kg
Propofol DexmedetomidineTotal Propofol Administered3.0 mg/kg

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026